{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:53:29Z","timestamp":1776329609531,"version":"3.50.1"},"reference-count":24,"publisher":"Baskent University","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.6002\/ect.2023.0010","type":"journal-issue","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:52:52Z","timestamp":1715568772000},"source":"Crossref","is-referenced-by-count":0,"title":[],"prefix":"10.6002","volume":"22","member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; the Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-1977. doi:10.1056\/NEJMoa060068","DOI":"10.1056\/NEJMoa060068"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Chouhan KK, Zhang R. Antibody induction therapy in adult kidney transplantation: a controversy continues. World J Transplant. 2012;2(2):19-26. doi:10.5500\/wjt.v2.i2.19","DOI":"10.5500\/wjt.v2.i2.19"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Claeys E, Vermeire K. Immunosuppressive drugs in organ transplantation to prevent allograft rejection: mode of action and side effects. J Immunol Sci. 2019;3(4):14-21. doi:10.29245\/2578-3009\/2019\/4.1178","DOI":"10.29245\/2578-3009\/2019\/4.1178"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Neuwirt H, Rudnicki M, Schratzberger P, Pirklbauer M, Kronbichler A, Mayer G. Immunosuppression after renal transplantation. Memo. 2019;12:216-221. doi:10.1007\/s12254-019-0507-4","DOI":"10.1007\/s12254-019-0507-4"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Koyawala N, Silber JH, Rosenbaum PR, et al. Comparing outcomes between antibody induction therapies in kidney transplantation. J Am Soc Nephrol. 2017;28(7):2188-2200. doi:10.1681\/ASN.2016070768","DOI":"10.1681\/ASN.2016070768"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Liu Y, Zhou P, Han M, Xue CB, Hu XP, Li C. Basiliximab or antithymocyte globulin for induction therapy in kidney transplantation: a meta-analysis. Transplant Proc. 2010;42(5):1667-1670. doi:10.1016\/j.transproceed.2010.02.088","DOI":"10.1016\/j.transproceed.2010.02.088"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Kesiraju S, Paritala P, Rao Ch UM, Athmakuri SM, Reddy VS, Sahariah S. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: long-term outcome. Saudi J Kidney Dis Transpl. 2014;25(1):9-15. doi:10.4103\/1319-2442.124459","DOI":"10.4103\/1319-2442.124459"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Ulrich F, Niedzwiecki S, Pascher A, et al. Long-term outcome of ATG vs. basiliximab induction. Eur J Clin Invest. 2011;41(9):971-978. doi:10.1111\/j.1365-2362.2011.02490.x","DOI":"10.1111\/j.1365-2362.2011.02490.x"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Wang K, Xu X, Fan M. Induction therapy of basiliximab versus antithymocyte globulin in renal allograft: a systematic review and meta-analysis. Clin Exp Nephrol. 2018;22(3):684-693. doi:10.1007\/s10157-017-1480-z","DOI":"10.1007\/s10157-017-1480-z"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Willoughby LM, Schnitzler MA, Brennan DC, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: application of statistical approaches to reduce bias in observational comparisons. Transplantation. 2009;87(10):1520-1529. doi:10.1097\/TP.0b013e3181a484d7","DOI":"10.1097\/TP.0b013e3181a484d7"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Kidney Disease: Improving Global Outcomes Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009;9 Suppl 3:S1-155. doi:10.1111\/j.1600-6143.2009.02834.x","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Dalal P, Shah G, Chhabra D, Gallon L. Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients. Int J Nephrol Renovasc Dis. 2010;3:107-115. doi:10.2147\/ijnrd.s7044","DOI":"10.2147\/IJNRD.S7044"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Hellemans R, Bosmans JL, Abramowicz D. Induction therapy for kidney transplant recipients: do we still need anti-IL2 receptor monoclonal antibodies? Am J Transplant. 2017;17(1):22-27. doi:10.1111\/ajt.13884","DOI":"10.1111\/ajt.13884"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Liapis H, Storch GA, Hill DA, Rueda J, Brennan DC. CMV infection of the renal allograft is much more common than the pathology indicates: a retrospective analysis of qualitative and quantitative buffy coat CMV-PCR, renal biopsy pathology and tissue CMV-PCR. Nephrol Dial Transplant. 2003;18(2):397-402. doi:10.1093\/ndt\/18.2.397","DOI":"10.1093\/ndt\/18.2.397"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Tanriover B, Zhang S, MacConmara M, et al. Induction therapies in live donor kidney transplantation on tacrolimus and mycophenolate with or without steroid maintenance. Clin J Am Soc Nephrol. 2015;10(6):1041-1049. doi:10.2215\/CJN.08710814","DOI":"10.2215\/CJN.08710814"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Ali H, Sharma A, Halawa A. Effect of interleukin-2 receptor antibody induction therapy on survival in renal transplant patients receiving tacrolimus. Am J Nephrol. 2020;51(5):366-372. doi:10.1159\/000506970","DOI":"10.1159\/000506970"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Lim WH, Chadban SJ, Campbell S, Dent H, Russ GR, McDonald SP. Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients. Nephrology (Carlton). 2010;15(3):368-376. doi:10.1111\/j.1440-1797.2009.01259.x","DOI":"10.1111\/j.1440-1797.2009.01259.x"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Evans RDR, Lan JH, Kadatz M, et al. Use and outcomes of induction therapy in well-matched kidney transplant recipients. Clin J Am Soc Nephrol. 2022;17(2):271-279. doi:10.2215\/CJN.09170721","DOI":"10.2215\/CJN.09170721"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Gavela Martinez E, Avila Bernabeu AI, Sancho Calabuig A, Beltran Catalan S, Escudero Quesada V, Pallardo Mateu LM. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression. Transplant Proc. 2009;41(6):2337-2338. doi:10.1016\/j.transproceed.2009.06.063","DOI":"10.1016\/j.transproceed.2009.06.063"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Janigen BM, Gehrmann S, Glatz T, et al. Evidence of interleukin-2-receptor-antibody induction in low-risk living donor kidney transplantation: a single-center pilot study. Transplant Proc. 2020;52(3):780-784. doi:10.1016\/j.transproceed.2020.01.036","DOI":"10.1016\/j.transproceed.2020.01.036"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Kim SJ, Rhu J, Yoo H, Kim K, Lee KW, Park JB. Outcome comparison between low-dose rabbit anti-thymocyte globulin and basiliximab in low-risk living donor kidney transplantation. J Clin Med. 2020;9(5). doi:10.3390\/jcm9051320","DOI":"10.3390\/jcm9051320"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Pham C, Kuten SA, Knight RJ, Nguyen DT, Graviss EA, Gaber AO. Assessment of infectious complications in elderly kidney transplant recipients receiving induction with anti-thymocyte globulin vs basiliximab. Transpl Infect Dis. 2020;22(3):e13257. doi:10.1111\/tid.13257","DOI":"10.1111\/tid.13257"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Baek CH, Kim JH, Yu H, et al. Usefulness of tacrolimus without basiliximab in well-matched living-donor renal transplant recipients in Korea. Exp Clin Transplant. 2016;14(4):389-393. doi:10.6002\/ect.2015.0271","DOI":"10.6002\/ect.2015.0271"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. de Sandes-Freitas TV, Felipe CR, de Franco MF, Tedesco-Silva H, Medina-Pestana JO. Basiliximab induction in patients receiving tacrolimus-based immunosuppressive regimens. Int Urol Nephrol. 2013;45(2):537-546. doi:10.1007\/s11255-012-0298-6","DOI":"10.1007\/s11255-012-0298-6"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T04:13:35Z","timestamp":1715573615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ectrx.org\/detail\/archive\/2024\/22\/4\/0\/270\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2023.0010","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}